Article Title: Safety and Efficacy of Gevokizumab in Patients with Behçet’s Disease Uveitis: Results of an Exploratory Phase 2 Study
Authors: Ilknur Tugal-Tutkun, Sibel Kadayifcilar, Moncef Khairallah, Sung Chul Lee, Pinar Ozdal, Yilmaz Özyazgan, Ji Hun Song, Hyeong Gon Yu, Valerie Lehner, Agnès de Cordoue, Oana Bernard, and Ahmet Gül
Journal: Ocular Immunology & Inflammation
Bibliometrics: Volume 25, Issue 1, 2017, pages 62–70
DOI: 10.3109/09273948.2015.1092558
Publisher: Taylor & Francis
This article included the following Declaration of Interest and Author Contribution sections:
DECLARATION OF INTEREST
Ahmet Gül has received lecture fees, honoraria and travel grants from Servier and Novartis. Sibel Kadayifcilar has acted as an investigator for Servier, Santen, Novartis, and Bayer, and has received travel grants from Novartis, Allergan, and Bayer, and honoraria for advisory board meetings from Bayer and Allergan. Moncef Khairallah has acted as a consultant for Servier. Sung Chul Lee, none. Pinar Ozdal, none. Yilmaz Özyazgan is Consultant for the Advisory Board of Servier. Ji Hun Song has received lecture fees from Allergan and a travel grant from Servier. Ilknur Tugal-Tutkun has received lecture fees, honoraria and travel grants from Servier. Valerie Lehner, Agnès de Cordoue and Oana Bernard are employees of Servier. Hyeong Gon Yu, none.
AUTHOR CONTRIBUTIONS
All authors participated in the study design, interpretation of the results, development and writing of the manuscript, and the decision to submit for publication. The sponsor was responsible for data management and the final data analyses.
The article should also have included the following funding section. The publisher apologizes for this error.
FUNDING
This study was funded by Servier.